Flannelly Barry P 4

What Happened

• Barry P. Flannelly, a director of Protara Therapeutics, received a compensatory award of 31,000 shares on 2026-06-15. The shares were granted at $0.00 (derivative award) and have a reported initial value of $0 in the Form 4 filing. This is a director equity grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-15; filing date: 2026-06-16 (filed the next day).
• Transaction type/code: Award/Grant (A); Price reported $0.00; reported transaction value $0 (derivative).
• Vesting: The shares vest in full on the first anniversary of the grant subject to continuous board service, and will vest in full upon a Change of Control (per filing footnote).
• Shares owned after transaction: Not specified in the filing.
• Timeliness: Filing appears timely (Form 4 filed within required 2 business days).

Context

• This was a compensatory restricted stock award for a director, which is standard executive/director compensation and not the same as an insider buying shares in the open market. Such grants reflect company compensation practices rather than a direct cash investment by the insider.